GILEAD SCIENCES, INC. Proceeds from Debt, Net of Issuance Costs
GILEAD SCIENCES, INC. (GILD) reported Proceeds from Debt, Net of Issuance Costs of $4.08 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-08-06
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for the quarter ending 2024-12-31 was $3.46B, a 346300.00% increase year-over-year.
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for the quarter ending 2023-12-31 was $1.00M.
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for the quarter ending 2022-12-31 was $0.00.
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for fiscal 2024 was $3.46B, a 74.95% increase from fiscal 2023.
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for fiscal 2023 was $1.98B.
- GILEAD SCIENCES, INC. proceeds from debt, net of issuance costs for fiscal 2022 was $0.00.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 3 month as first filed | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 6 month as first filed | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 9 month as first filed | Proceeds from Debt, Net of Issuance Costs 12 month | Proceeds from Debt, Net of Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.08B 10-Q · filed 2026-08-06 | |||||||
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 | |||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |||||||
| 2024-12-31 | $3.46B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.46B 10-K · filed 2026-02-24 | ||||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||||||
| 2023-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.98B 10-K · filed 2026-02-24 | ||||||
| 2023-09-30 | $1.98B 10-Q · filed 2024-11-12 | |||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | ||||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | |||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $0.00 10-K · filed 2024-02-23 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-03 | |||||||
| 2020-12-31 | $995.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $8.18B 10-K · filed 2023-02-22 | ||||||
| 2020-09-30 | $7.19B 10-Q · filed 2021-11-03 | |||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $0.00 10-K · filed 2022-02-23 | ||||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 | |||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 | ||||||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 | |||||||
| 2017-12-31 | $5.99B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $8.98B derived: sum of 2 quarters · filed 2020-02-25 | $8.98B 10-K · filed 2020-02-25 | |||||
| 2017-09-30 | $2.99B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.99B 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-07 | |||||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $4.94B derived: sum of 2 quarters · filed 2019-02-26 | $5.29B 10-K · filed 2019-02-26 | |||||
| 2016-09-30 | $4.94B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $5.29B 10-Q · filed 2017-11-07 | ||||||
| 2016-06-30 | $349.00M 10-Q · filed 2017-08-07 | |||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $9.90B derived: sum of 2 quarters · filed 2018-02-27 | $9.90B derived: sum of 3 quarters · filed 2018-02-27 | $9.90B 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $9.90B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $9.90B derived: sum of 2 quarters · filed 2016-11-07 | $9.90B 10-Q · filed 2016-11-07 | $13.87B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | $3.97B derived: sum of 3 quarters · filed 2017-02-27 | $3.97B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $3.97B derived: sum of 2 quarters · filed 2017-02-27 | $3.97B derived: sum of 3 quarters · filed 2017-02-27 | $3.96B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $3.97B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $3.97B derived: sum of 2 quarters · filed 2017-02-27 | $3.96B derived: sum of 3 quarters · filed 2017-02-27 | $7.93B 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$3.00M derived: sum of 2 quarters · filed 2015-11-04 | $3.96B 10-Q · filed 2015-11-04 | $3.97B 10-Q · filed 2014-11-05 | $3.96B derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-06-30 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $3.97B 10-Q · filed 2015-08-05 | $3.97B 10-Q · filed 2014-08-04 | $3.97B derived: sum of 3 quarters · filed 2016-02-24 | $3.97B derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-03-31 | $3.97B 10-Q · filed 2015-05-08 | $3.97B 10-Q · filed 2014-05-07 | $3.97B derived: sum of 2 quarters · filed 2016-02-24 | $3.97B derived: sum of 3 quarters · filed 2016-02-24 | $3.97B derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $0.00 derived: sum of 2 quarters · filed 2016-02-24 | $0.00 derived: sum of 3 quarters · filed 2016-02-24 | $0.00 10-K · filed 2016-02-24 | ||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $0.00 derived: sum of 2 quarters · filed 2014-11-05 | $0.00 10-Q · filed 2014-11-05 | -$733.00K derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $0.00 10-Q · filed 2014-08-04 | -$733.00K derived: sum of 3 quarters · filed 2015-02-25 | -$733.00K derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-07 | -$733.00K derived: sum of 2 quarters · filed 2015-02-25 | -$733.00K derived: sum of 3 quarters · filed 2015-02-25 | -$733.00K derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | -$733.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | -$733.00K derived: sum of 2 quarters · filed 2015-02-25 | -$733.00K derived: sum of 3 quarters · filed 2015-02-25 | $2.14B 10-K · filed 2015-02-25 | $2.14B 10-K · filed 2014-02-25 | |||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $0.00 derived: sum of 2 quarters · filed 2013-10-31 | $2.14B 10-Q · filed 2013-10-31 | |||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $2.14B 10-Q · filed 2013-08-01 | ||||||
| 2012-03-31 | $2.14B 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | $4.66B 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |